FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029696545> ?p ?o ?g. }

• W2029696545 endingPage "1027" @default.
• W2029696545 startingPage "1009" @default.
• W2029696545 abstract "In Brief Purpose: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation. Methods: Three hundred and forty-five eyes with a visual acuity of 20/320 or better, center-involved diabetic macular edema receiving focal/grid laser, and diabetic retinopathy receiving prompt panretinal photocoagulation were randomly assigned to sham (n = 123), 0.5-mg ranibizumab (n = 113) at baseline and 4 weeks, and 4-mg triamcinolone at baseline and sham at 4 weeks (n = 109). Treatment was at investigator discretion from 14 weeks to 56 weeks. Results: Mean changes (±SD) in visual acuity letter score from baseline were significantly better in the ranibizumab (+1 ± 11; P < 0.001) and triamcinolone (+2 ± 11; P < 0.001) groups compared with those in the sham group (−4 ± 14) at the 14-week visit, mirroring retinal thickening results. These differences were not maintained when study participants were followed for 56 weeks for safety outcomes. One eye (0.9%; 95% confidence interval, 0.02%-4.7%) developed endophthalmitis after receiving ranibizumab. Cerebrovascular/cardiovascular events occurred in 4%, 7%, and 3% of the sham, ranibizumab, and triamcinolone groups, respectively. Conclusion: The addition of 1 intravitreal triamcinolone injection or 2 intravitreal ranibizumab injections in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation is associated with better visual acuity and decreased macular edema by 14 weeks. Whether continued long-term intravitreal treatment is beneficial cannot be determined from this study. Intravitreal triamcinolone or ranibizumab was associated with better visual acuity and decreased macular edema at 14 weeks after randomization compared with sham in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation. Injections were not continued beyond 4 weeks; expectedly, their effects were not maintained at the 34-week and 56-week safety visits." @default.
• W2029696545 created "2016-06-24" @default.
• W2029696545 creator A5012372938 @default.
• W2029696545 creator A5023376839 @default.
• W2029696545 creator A5029257998 @default.
• W2029696545 creator A5039879095 @default.
• W2029696545 creator A5042011351 @default.
• W2029696545 creator A5059376308 @default.
• W2029696545 creator A5060053817 @default.
• W2029696545 creator A5068302775 @default.
• W2029696545 creator A5078751063 @default.
• W2029696545 creator A5081405643 @default.
• W2029696545 creator A5082261567 @default.
• W2029696545 creator A5082592591 @default.
• W2029696545 date "2011-06-01" @default.
• W2029696545 modified "2023-10-09" @default.
• W2029696545 title "RANDOMIZED TRIAL EVALUATING SHORT-TERM EFFECTS OF INTRAVITREAL RANIBIZUMAB OR TRIAMCINOLONE ACETONIDE ON MACULAR EDEMA AFTER FOCAL/GRID LASER FOR DIABETIC MACULAR EDEMA IN EYES ALSO RECEIVING PANRETINAL PHOTOCOAGULATION" @default.
• W2029696545 cites W1515929100 @default.
• W2029696545 cites W1526282761 @default.
• W2029696545 cites W1559170621 @default.
• W2029696545 cites W1973545783 @default.
• W2029696545 cites W1977480389 @default.
• W2029696545 cites W1988571866 @default.
• W2029696545 cites W2012564902 @default.
• W2029696545 cites W2017344150 @default.
• W2029696545 cites W2022886290 @default.
• W2029696545 cites W2038476909 @default.
• W2029696545 cites W2057880134 @default.
• W2029696545 cites W2057983131 @default.
• W2029696545 cites W2072964734 @default.
• W2029696545 cites W2083092631 @default.
• W2029696545 cites W2087899702 @default.
• W2029696545 cites W2097959988 @default.
• W2029696545 cites W2112669742 @default.
• W2029696545 cites W2148230234 @default.
• W2029696545 cites W2324588265 @default.
• W2029696545 cites W2406931263 @default.
• W2029696545 cites W2797733197 @default.
• W2029696545 cites W280258025 @default.
• W2029696545 cites W4232979084 @default.
• W2029696545 cites W4239471829 @default.
• W2029696545 cites W4240531687 @default.
• W2029696545 doi "https://doi.org/10.1097/iae.0b013e318217d739" @default.
• W2029696545 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3489032" @default.
• W2029696545 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21394052" @default.
• W2029696545 hasPublicationYear "2011" @default.
• W2029696545 type Work @default.
• W2029696545 sameAs 2029696545 @default.
• W2029696545 citedByCount "123" @default.
• W2029696545 countsByYear W20296965452012 @default.
• W2029696545 countsByYear W20296965452013 @default.
• W2029696545 countsByYear W20296965452014 @default.
• W2029696545 countsByYear W20296965452015 @default.
• W2029696545 countsByYear W20296965452016 @default.
• W2029696545 countsByYear W20296965452017 @default.
• W2029696545 countsByYear W20296965452018 @default.
• W2029696545 countsByYear W20296965452019 @default.
• W2029696545 countsByYear W20296965452020 @default.
• W2029696545 countsByYear W20296965452021 @default.
• W2029696545 countsByYear W20296965452022 @default.
• W2029696545 countsByYear W20296965452023 @default.
• W2029696545 crossrefType "journal-article" @default.
• W2029696545 hasAuthorship W2029696545A5012372938 @default.
• W2029696545 hasAuthorship W2029696545A5023376839 @default.
• W2029696545 hasAuthorship W2029696545A5029257998 @default.
• W2029696545 hasAuthorship W2029696545A5039879095 @default.
• W2029696545 hasAuthorship W2029696545A5042011351 @default.
• W2029696545 hasAuthorship W2029696545A5059376308 @default.
• W2029696545 hasAuthorship W2029696545A5060053817 @default.
• W2029696545 hasAuthorship W2029696545A5068302775 @default.
• W2029696545 hasAuthorship W2029696545A5078751063 @default.
• W2029696545 hasAuthorship W2029696545A5081405643 @default.
• W2029696545 hasAuthorship W2029696545A5082261567 @default.
• W2029696545 hasAuthorship W2029696545A5082592591 @default.
• W2029696545 hasBestOaLocation W20296965452 @default.
• W2029696545 hasConcept C118487528 @default.
• W2029696545 hasConcept C134018914 @default.
• W2029696545 hasConcept C141071460 @default.
• W2029696545 hasConcept C2776694085 @default.
• W2029696545 hasConcept C2777802072 @default.
• W2029696545 hasConcept C2778257484 @default.
• W2029696545 hasConcept C2778903070 @default.
• W2029696545 hasConcept C2779829184 @default.
• W2029696545 hasConcept C2780347916 @default.
• W2029696545 hasConcept C2781100027 @default.
• W2029696545 hasConcept C2908627140 @default.
• W2029696545 hasConcept C555293320 @default.
• W2029696545 hasConcept C71924100 @default.
• W2029696545 hasConceptScore W2029696545C118487528 @default.
• W2029696545 hasConceptScore W2029696545C134018914 @default.
• W2029696545 hasConceptScore W2029696545C141071460 @default.
• W2029696545 hasConceptScore W2029696545C2776694085 @default.
• W2029696545 hasConceptScore W2029696545C2777802072 @default.
• W2029696545 hasConceptScore W2029696545C2778257484 @default.
• W2029696545 hasConceptScore W2029696545C2778903070 @default.
• W2029696545 hasConceptScore W2029696545C2779829184 @default.
• W2029696545 hasConceptScore W2029696545C2780347916 @default.
• W2029696545 hasConceptScore W2029696545C2781100027 @default.

• next